Skip to main contentSkip to footer content
Back to all entries

German Federal Ministry of Education and Research („BMBF“) selects tiakis Biotech AG to develop Tiprelestat as a potential therapeutic for COVID-19.

tiakis Biotech AG (formerly Proteo Biotech AG) has announced that the German BMBF has selected the Company to conduct a clinical phase 1b/2 trial to develop its investigational medical product Tiprelestat as a potential therapeutic for COVID-19.

The aim of the clinical trial is to assess Tiprelestat’s efficacy to attenuate severe disease progression of COVID-19. The Company expects the clinical trial to commence in Q4 2022.

tiakis is very proud to support the ongoing efforts to develop treatment options for COVID-19 and to lessen the future impact of the pandemic. 

Read more in the PR release from the German BMBF:
https://www.bmbf.de/bmbf/shareddocs/pressemitteilungen/de/2021/12/231221-Therapeutika.html

Contact

tiakis BIOTECH AG
Sophienblatt 40
24103 Kiel
Germany
phone: +49 431 8888-462
fax: +49 431 8888-463
email: info@tiakis.bio